Insider · CIK 0001544589

Hooper Suzanne Sawochka

Reports to the SEC for 3 companies · DUBLIN 4, L2

sec.gov

Transactions

Companies

Filings

CIK

0001544589

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−24.2K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−78.4K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−24K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.8K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−38K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.6K sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCU Disposition from Tender	Director	UDisposition from Tender	−7,000 sh	—	—	0
2023-05-10	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+78.4K sh	—	—	78,407
2022-05-18	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+24.2K sh	—	—	24,222
2021-06-08	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+19.6K sh	—	—	19,619
2021-01-26	Eidos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.4K sh	—	—	0
2021-01-26	Eidos Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−4,526 sh	—	—	0
2020-08-06	Eidos Therapeutics, Inc.Restricted Stock UnitsA Award	Director	AAward	+4,526 sh	—	—	4,526
2020-08-06	Eidos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+21.4K sh	—	—	21,447
2020-05-20	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+16.8K sh	—	—	16,806
2019-05-15	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2019-05-15	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+38K sh	—	—	38,000
2019-04-08	NGM BIOPHARMACEUTICALS INCP Purchase	Director	PPurchase	+7,000 sh	$16.00	+$112K	7,000
2019-02-27	JAZZJazz Pharmaceuticals plc · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	−6,666 sh	—	—	28,671
2019-02-27	JAZZJazz Pharmaceuticals plcM Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	+6,666 sh	$46.83	+$312K	46,404
2019-02-27	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−6,666 sh	$140.00	−$933K	39,738
2019-02-26	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−663 sh	$127.76	−$84.7K	39,738
2019-02-25	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−783 sh	$126.25	−$98.9K	40,401
2018-12-14	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−39 sh	$140.21	−$5,468.19	41,184
2018-12-14	JAZZJazz Pharmaceuticals plc · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	−3,295 sh	—	—	35,337
2018-12-14	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−3,295 sh	$140.21	−$462K	41,223
2018-12-14	JAZZJazz Pharmaceuticals plcM Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	+3,295 sh	$46.83	+$154K	44,518
2018-05-14	JAZZJazz Pharmaceuticals plcM Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	+1,691 sh	$59.13	+$100K	40,978
2018-05-14	JAZZJazz Pharmaceuticals plcM Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	+8,540 sh	$46.83	+$400K	39,287
2018-05-14	JAZZJazz Pharmaceuticals plc · Incentive Stock Option (right to buy)M Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	−8,540 sh	—	—	0
2018-05-14	JAZZJazz Pharmaceuticals plc · Incentive Stock Option (right to buy)M Exercise/Conversion	EVP & General Counsel	MExercise/Conversion	−1,691 sh	—	—	0
2018-05-11	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−7,500 sh	$165.00	−$1.24M	30,747
2018-03-05	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−1,239 sh	$143.39	−$178K	38,247
2018-03-01	JAZZJazz Pharmaceuticals plc · Incentive Stock Option (right to buy)A Award	EVP & General Counsel	AAward	+710 sh	—	—	710
2018-03-01	JAZZJazz Pharmaceuticals plc · Non-Qualified Stock Option (right to buy)A Award	EVP & General Counsel	AAward	+22.8K sh	—	—	22,790
2018-03-01	JAZZJazz Pharmaceuticals plcA Award	EVP & General Counsel	AAward	+9,400 sh	—	—	39,486
2018-02-27	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−864 sh	$143.80	−$124K	30,086
2018-02-26	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−1,445 sh	$147.44	−$213K	30,950
2017-07-20	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−4,580 sh	$160.00	−$733K	32,322
2017-06-23	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−420 sh	$160.00	−$67.2K	36,902
2017-05-09	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−2,500 sh	$160.00	−$400K	37,149
2017-04-27	JAZZJazz Pharmaceuticals plcS Sale	EVP & General Counsel	SSale	−2,500 sh	$160.00	−$400K	39,649
2017-03-06	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−2,087 sh	$132.81	−$277K	42,149
2017-03-02	JAZZJazz Pharmaceuticals plc · Non-Qualified Stock Option (right to buy)A Award	EVP & General Counsel	AAward	+24.3K sh	—	—	24,266
2017-03-02	JAZZJazz Pharmaceuticals plc · Incentive Stock Option (right to buy)A Award	EVP & General Counsel	AAward	+734 sh	—	—	734
2017-03-02	JAZZJazz Pharmaceuticals plcA Award	EVP & General Counsel	AAward	+10K sh	—	—	44,236
2017-02-27	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−2,511 sh	$136.97	−$344K	69,236
2016-08-09	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−4,565 sh	$150.01	−$685K	36,699
2016-03-07	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP & General Counsel	FTax Payment	−1,832 sh	$127.84	−$234K	41,141

Recent filings

Accepted (ET)
Apr 84
Hooper Suzanne Sawochka0000950170-24-042600
SEC(opens sec.gov)
May 124
Hooper Suzanne Sawochka0001209191-23-029187
SEC(opens sec.gov)
May 204
Hooper Suzanne Sawochka0001209191-22-031134
SEC(opens sec.gov)
Jun 104
Hooper Suzanne Sawochka0001209191-21-039587
SEC(opens sec.gov)
Jan 284
Hooper Suzanne Sawochka0000899243-21-003642
SEC(opens sec.gov)
Aug 104
Hooper Suzanne Sawochka0000899243-20-021958
SEC(opens sec.gov)
May 224
Hooper Suzanne Sawochka0001209191-20-031871
SEC(opens sec.gov)
May 174
Hooper Suzanne Sawochka0001209191-19-030719
SEC(opens sec.gov)
Apr 104
Hooper Suzanne Sawochka0001209191-19-024200
SEC(opens sec.gov)
Feb 274
Hooper Suzanne Sawochka0001765581-19-000015
SEC(opens sec.gov)

Companies

Address

C/O JAZZ PHARMACEUTICALS PLC CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4

DUBLIN 4, L2